MRI-Guided InterventionsRight Where You See Patients.
Global presence.
Thousands of patients treated.
AI enabled imaging.
AI-assisted targeting and robotics are not yet cleared for commercial use.
The Point of Care MRI managing the entire patient care continuum.
The FDA 510(k) cleared Promaxo MRI platform delivers MRI-guided prostate transperineal biopsies and treatment at the clinical setting of choice. With 77% cancer detection rates versus 40% for standard-of-care TRUS biopsy1, Promaxo identifies cancer that traditional approaches miss.
From screening through biopsy to targeted treatment and follow-up, Promaxo manages the complete patient care pathway — combining point-of-care MRI, AI-assisted planning, and robotics-enabled accuracy*.
Up to 7x higher reimbursement for biopsies and treatment compared to the standard of care.
Promaxo enables urologists to bill MRI-guided CPT codes (55713 & 55715) or (55714 & 55715) with the option to use additional MR imaging codes.
reimbursement vs Standard of Care
reimbursement vs Standard of Care
Available for clinic, ASC, or OR
Clinical Superiority.
Attractive Economics.3
Complete Patient Care Pathway.4
*AI-powered screening and robotic guidance are not yet cleared for commercial use.
77% Cancer Detection
93% improvement over standard of care. 23% more clinically significant cancers identified. 33% upstaging at biopsy.1,2
Enhanced Patient Experience
Transperineal approach eliminates the 7% infection risk of transrectal biopsy. Thousands of patients treated to date.
Up to 7x Reimbursement
New CPT codes (55713 & 55715) or (55714 & 55715) optionally combined with MR imaging code. Up to 2x with private payers over CMS. Brings targeted treatment to point-of-care for the first time.
MRI + AI + Robotics*
250+ patents. 30+ peer-reviewed publications. An integrated platform spanning biopsy, treatment, and AI-driven screening.*
AI-driven screening, diagnosis, treatment, and follow-up.
Deep learning models analyze MR images for automated cancer grading. AI-powered tissue characterization enables earlier, more accurate treatment decisions. Robotics guides biopsy and treatment needles into position under live MRI.
Robot and AI tissue characterization are not cleared for commercial use.
AI-Driven Insights
MRI-Compatible Robot
Demonstrated clinical superiority
over standard of care.
77% cancer detection rate1. 30+ peer-reviewed publications. Global system deployment across private practices, ASCs, IDNs, and academic institutions.
Ready to bring MRI-Guided interventions into your practice?
See the platform live, model the economics for a future practice, or get the billing details. Everything you need to take the next step.
Schedule a Live Demo
See the Promaxo platform in action — at your practice, at a regional event, or virtually. Meet the team and get your questions answered.
Site Planning Tool
Estimate site-level economics using transparent assumptions for procedure volume, payer mix, and operating costs.
Reimbursement Guide
Biopsy CPT codes (55713, 55714, & 55715 codes) and MRI imaging CPT codes (72195, 76376, & 77021), billing pathway details, and payer coverage documentation.